Plain-English translation of NCT07381660 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a newer, highly precise form of radiation therapy called stereotactic body radiotherapy (SBRT) works as well as or better than traditional surgical removal for treating small liver cancers. SBRT uses advanced technology to deliver intense radiation directly to the tumor while sparing healthy liver tissue. The study will follow patients over time to compare how well each approach controls the cancer and affects overall survival.
While surgery has long been the standard treatment for small liver cancers, it carries real risks—especially bleeding, infection, and liver failure—and isn't safe for all patients. This treatment is a newer option that might offer similar cancer control with fewer serious side effects, particularly for people who are too frail for surgery or have had cancer come back before.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either surgical resection (where a surgeon removes the tumor and surrounding liver tissue) or SBRT (where you receive several sessions of focused radiation therapy over 1–2 weeks). You will then be followed closely with imaging scans and blood tests to monitor how well the treatment works and to watch for any side effects. The study team will track your overall survival and quality of life over time to compare which approach gives patients the best outcomes.
AI-generated summary from trial data · Nov 17, 2026 · Not medical advice
China